Planned Parenthood Withdraws From Federal Family Planning Program
Planned Parenthood is withdrawing from the U.S. government’s family planning program.
Contraception
Oral Contraceptive Recalled Because of Possibility of Reduced Efficacy
The product is being recalled due to out-of-specification dissolution results at the 3-month stability time point.
Similar HIV Risk Profiles With Depot Medroxyprogesterone, Copper IUDs, Levonorgestrel Implants
The similar rates of HIV risk among a population of African woman using intramuscular depot medroxyprogesterone acetate, copper intrauterine devices, and levonorgestrel implants highlights the need for HIV prevention to be incorporated into contraceptive practices.
Progestin-Only Contraceptive Slynd Gets FDA Approval
Slynd contains drospirenone, a spironolactone analogue.
NDA for Twirla Contraceptive Patch Resubmitted to FDA
Agile Therapeutics has resubmitted to the Food and Drug Administration (FDA) the New Drug Application (NDA) for its product, Twirla, an investigational low-dose combined hormonal contraceptive patch (AG200-15). Based on the results from a comparative wear study, the resubmitted NDA will address the FDA’s questions on in vivo adhesion, additional information on the Company’s manufacturing…
Oral Contraceptives Offer Some Protection Against Bone Loss in Anorexia Nervosa
For young women with anorexia nervosa, oral contraceptives may limit bone loss.
New Title X Rule Threatens Contraceptive Access for American Women
A new rule by the Trump administration may make it more challenging for women to access contraceptive services, despite evidence of the benefits to women, families, and the nation as a whole.
Novel Androgen May Be a Potential Candidate for Male Hormonal Contraceptive
11β-MNTDC is a modified testosterone with androgenic and progestational activity that is being developed as a potential male contraceptive.
Genetic Variant May Put Some Women at Increased Risk for Contraception Failure
A genetic variant may play a major role in why hormonal contraception fails in some women, according to a new study published in Obstetrics & Gynecology.
Oral Contraceptive Product Recalled Due to Packaging Error
Apotex announced a voluntary recall of 4 lots of Drospirenone and Ethinyl Estradiol Tablets 3mg/0.03mg due to the possibility of defective blisters with incorrect tablet arrangements and/or empty blister pockets.
Next post in General Endocrinology
